BridgeBio Oncology Therapeutics Inc.
BBOTNASDAQHealthcare● Active
$7.78
$-0.03(-0.38%)
Market Cap$623233269
P/E Ratio—
52W High$14.87
52W Low$7.6
BridgeBio Oncology Therapeutics Inc. (BBOT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BBOT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Jun 4, 2026EPS Actual
-$0.53
Est. -$0.51 · -2.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Jun 4, 2026
After Market Close
▼ Miss EPS
BBOT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.54 | — | — | — | — | — |
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.54 | — | — | — | — | — |
| ▼ Q2 FY2026 | Jun 4, 2026 | -$0.51 | -$0.53 | -2.8% | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.51 | -$0.49 | +4.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.41 | -$1.03 | -151.2% | — | — | — |
| — Q3 FY2025 | Aug 1, 2025 | — | $0.04 | — | — | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$0.02 | — | — | — | — |
| — Q1 FY2025 | Mar 11, 2025 | — | $0.12 | — | — | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.54
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.54
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 4, 2026Miss
EPS Actual
-$0.53
EPS Est.
-$0.51
EPS Surpr.
-2.8%
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.49
EPS Est.
-$0.51
EPS Surpr.
+4.5%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$1.03
EPS Est.
-$0.41
EPS Surpr.
-151.2%
Revenue
—
Q3 FY2025
Aug 1, 2025
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 15, 2025
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 11, 2025
EPS Actual
$0.12
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.40 | $-0.40 | $-0.40 | 2 |
| Q3 FY2028 | $-0.40 | $-0.40 | $-0.40 | 2 |
| Q2 FY2028 | $-0.39 | $-0.39 | $-0.39 | 2 |
| Q1 FY2028 | $-0.39 | $-0.39 | $-0.39 | 2 |
| Q4 FY2027 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2027 | $-0.51 | $-0.51 | $-0.51 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Jun 4, 2026 | -2.8% | $8.03 | $8.23 | +2.49% |
| ▲ Q2 FY2026 | May 12, 2026 | +4.5% | $7.89 | $8.13 | +3.04% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -151.2% | $12.75 | $12.63 | -0.94% |
| — Q3 FY2025 | Aug 1, 2025 | — | $10.60 | $10.43 | -1.60% |
| — Q2 FY2025 | May 15, 2025 | — | $10.85 | $10.85 | +0.00% |
| — Q1 FY2025 | Mar 11, 2025 | — | $10.70 | $10.70 | +0.00% |
| — Q4 FY2024 | Nov 14, 2024 | — | $10.53 | $10.53 | +0.00% |
| — Q3 FY2024 | Aug 14, 2024 | — | $10.40 | $10.40 | +0.00% |
Q2 FY2026+2.49%
Report Date
Jun 4, 2026
EPS Beat/Miss
-2.8%
Price Before
$8.03
Price After
$8.23
Q2 FY2026+3.04%
Report Date
May 12, 2026
EPS Beat/Miss
+4.5%
Price Before
$7.89
Price After
$8.13
Q4 FY2025-0.94%
Report Date
Nov 12, 2025
EPS Beat/Miss
-151.2%
Price Before
$12.75
Price After
$12.63
Q3 FY2025-1.60%
Report Date
Aug 1, 2025
EPS Beat/Miss
—
Price Before
$10.60
Price After
$10.43
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$10.85
Price After
$10.85
Q1 FY2025+0.00%
Report Date
Mar 11, 2025
EPS Beat/Miss
—
Price Before
$10.70
Price After
$10.70
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$10.53
Price After
$10.53
Q3 FY2024+0.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
—
Price Before
$10.40
Price After
$10.40
Avg Beat Reaction+3.04%
Avg Miss Reaction+0.78%
Beat Rate1 / 8 quarters
Largest Move+3.04% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BBOT ends December
BridgeBio Oncology Therapeutics Inc. (BBOT) most recently reported earnings on June 4, 2026 for Q2 FY2026, posting EPS of $-0.53 — missing the analyst consensus of $-0.51 by -2.8%. The next BBOT earnings date is expected around September 1, 2026.
Each quarter, investors track BBOT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BBOT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BBOT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BBOT earnings · 5 questionsBridgeBio Oncology Therapeutics Inc.'s next earnings report is expected around September 1, 2026. BBOT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BBOT historically reports after market close (AMC).
BBOT earnings datewhen is BBOT earningsBBOT next earnings datewhen does BBOT report earningsBBOT earnings calendar
▸ Source: FMP · BridgeBio Oncology Therapeutics Inc. SEC filings · US GAAP · BridgeBio Oncology Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026